Details for Patent: 8,357,713
✉ Email this page to a colleague
Which drugs does patent 8,357,713 protect, and when does it expire?
Patent 8,357,713 protects DUZALLO and ZURAMPIC and is included in two NDAs.
This patent has ninety-two patent family members in thirty-seven countries.
Summary for Patent: 8,357,713
| Title: | Compounds and compositions and methods of use |
| Abstract: | Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid. |
| Inventor(s): | Quart; Barry D. (Encinitas, CA), Girardet; Jean-Luc (San Diego, CA), Gunic; Esmir (San Diego, CA), Yeh; Li-Tain (Irvine, CA) |
| Assignee: | Ardea Biosciences Inc. (San Diego, CA) |
| Application Number: | 13/174,568 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Use; Dosage form; |
Drugs Protected by US Patent 8,357,713
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ironwood Pharms Inc | DUZALLO | allopurinol; lesinurad | TABLET;ORAL | 209203-001 | Aug 18, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE | ⤷ Sign Up | |||
| Ironwood Pharms Inc | DUZALLO | allopurinol; lesinurad | TABLET;ORAL | 209203-002 | Aug 18, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE | ⤷ Sign Up | |||
| Ironwood Pharms Inc | ZURAMPIC | lesinurad | TABLET;ORAL | 207988-001 | Dec 22, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | REDUCTION OF SERUM URIC ACID LEVELS | ⤷ Sign Up | |||
| Ironwood Pharms Inc | ZURAMPIC | lesinurad | TABLET;ORAL | 207988-001 | Dec 22, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF HYPERURICEMIA | ⤷ Sign Up | |||
| Ironwood Pharms Inc | ZURAMPIC | lesinurad | TABLET;ORAL | 207988-001 | Dec 22, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF GOUT | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,357,713
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2217577 | ⤷ Sign Up | 2016016 | Norway | ⤷ Sign Up |
| European Patent Office | 2217577 | ⤷ Sign Up | CA 2019 00003 | Denmark | ⤷ Sign Up |
| European Patent Office | 2217577 | ⤷ Sign Up | PA2019003 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2217577 | ⤷ Sign Up | 300970 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2217577 | ⤷ Sign Up | 2019C/502 | Belgium | ⤷ Sign Up |
| European Patent Office | 2217577 | ⤷ Sign Up | 122019000008 | Germany | ⤷ Sign Up |
| European Patent Office | 2217577 | ⤷ Sign Up | LUC00103 | Luxembourg | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
